{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:32:19Z","timestamp":1785583939748,"version":"3.56.0"},"reference-count":8,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v106.adv-2025-0279","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:15:39Z","timestamp":1776690939000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Ulceronecrotic Evolution during Mogamulizumab Treatment in a Patient with Primary Cutaneous Peripheral T-cell Lymphoma"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-5493","authenticated-orcid":false,"given":"Quentin","family":"Samaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilou","family":"Dubo\u00eblle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Marque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7960-068X","authenticated-orcid":false,"given":"Virginie","family":"Bres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8736-1922","authenticated-orcid":false,"given":"Olivier","family":"Dereure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"150573","doi-asserted-by":"crossref","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192\u20131204.","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"150574","unstructured":"Poteligeo. European Medicines Agency (EMA). 2018. [cited 2025 November 21]. Available from: https:\/\/www.ema. europa.eu\/en\/medicines\/human\/EPAR\/poteligeo"},{"key":"150575","doi-asserted-by":"crossref","unstructured":"Kempf W, Mitteldorf C, Cerroni L, Willemze R, Berti E, Guenova E, et al. Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group. J Eur Acad Dermatol Venereol 2024; 38: 1491\u20131503.","DOI":"10.1111\/jdv.19987"},{"key":"150576","doi-asserted-by":"crossref","unstructured":"G, Roccuzzo G, Pileri A, Agostinelli C, Maronese CA, Aquino C, et al. Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: a systematic review. J Eur Acad Dermatol Venereol 2024; 38: 1738\u20131748.","DOI":"10.1111\/jdv.19801"},{"key":"150577","doi-asserted-by":"crossref","unstructured":"Hansen I, Abeck F, Menz A, Schneider SW, Booken N. Mogamulizumab-associated rash - case series and review of the literature. J Dtsch Dermatol Ges 2024; 22: 1079\u20131086.","DOI":"10.1111\/ddg.15432"},{"key":"150578","doi-asserted-by":"crossref","unstructured":"Barr\u00e9 M, Valois A, Okhremchuk I, Sair M, Masbou J, Abed S, et al. Ecthyma gangrenosum complicating mogamulizumab treatment of S\u00e9zary syndrome. Ann Dermatol Venereol 2021; 148: 63\u201365.","DOI":"10.1016\/j.annder.2020.09.576"},{"key":"150579","unstructured":"B\u00e9gaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111\u2013118."},{"key":"150580","doi-asserted-by":"crossref","unstructured":"Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, et al. Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T-cell leukemialymphoma. Clin Cancer Res 2019; 25: 4388\u20134399.","DOI":"10.1158\/1078-0432.CCR-18-2575"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45956\/53566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45956\/53567","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45956\/53568","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/45956\/53566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:15:49Z","timestamp":1776690949000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/45956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":8,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2025-0279","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}